Loading…

Genfit SAGNFT.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Biotechnology
Momentum strong 66
Mkt cap
$571M
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$3.58M
20-day average traded
Fwd P/E
431.5×
forward earnings
ROIC−WACC
n/a
WACC 11.1%
Hurdle
-104 pp
Req g minus delivered
Next earnings
141 days
8 Apr 2027
Close · EUR€10.42
1D+2.0%
1W-4.8%
1M+15.8%
3M-27.7%
6M+22.2%
YTD+97.9%
1Y+179.1%
ATR %6.4%
52w lowhigh32.7% off high

What Genfit does

Employees: 192

Genfit at a glance

Size Genfit (GNFT.PA) is a France Health Care company (Biotechnology) with a market value of $571M, the 169th largest of 206 France companies the cockpit tracks. Shares closed at €10.42 on 18 Nov 2026.

Performance Over six months the shares gained 22.2%, against -20.4% for the median peer and -2.1% for the France market (cap-weighted) — 3rd highest of 19 in its peer set.

Growth Revenue grew 27.7% over the last twelve months (peer median +7.7%); the operating margin is -130.4% (peer median -10.7%).

Valuation It trades at 431.5× forward earnings against a peer median of 21.5× (most expensive of 8).

Price implies For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +143%, so the hurdle is -104 pp: the price already allows for a slowdown.

Next results Next results expected around 8 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026GNFT.PA 122Peer median 79
Six months, rebased to 100: Genfit against the median of its 20 peers (local-currency closes).

Genfit financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€53.0M€65.4M€67.0M€28.6M€20.2M
Revenue growth—-2%+135%+41%—
Gross profit€1.01M€14.6M€65.3Mn/an/a
EBITDA-€17.1M-€8.04M€1.39M-€34.9M-€31.2M
Net income-€102M-€86.0M€1.51M-€28.9M-€23.7M
Free cash flow€7.50M-€26.7M€14.2M-€56.3M-€74.7M
Capital expenditure€914,000€3.42M€979,000€2.49M€0
Total debtn/a€151M€62.1M€70.2M€75.3M

Quarterly statements and history in the cockpit →

Genfit competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-50%0%+50%+100%1672FDMT300404SANA300871WVECLYM1521SRZN603387JANXGERNGNFT.PA6-month return →1-month return →
Up and to the right = strong over both horizons. Genfit is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×200×400×3004043008711521688639002880GERN300858GNFT.PARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Genfit is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%3004041521603387GNFT.PAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Genfit is the large dot.

Genfit competitors and peer comparison

How Genfit compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Genfit against its 20 peers (data as of 18 Nov 2026)
MeasureGNFT.PAPeer medianRank in peer set
1-month return+15.8%-14.3%4th highest of 21
6-month return+22.2%-20.4%3rd highest of 19
Distance from 52-week high-32.7%-50.5%4th highest of 21
Revenue growth (TTM)+27.7%+7.7%6th highest of 17
Operating margin-130.4%-10.7%7th lowest of 17
Forward P/E431.5×21.5×most expensive of 8
Growth the price implies (Req g, 7 yrs)39.8%14.3%most demanding of 4
Growth delivered (Del g)+143.5%+15.4%highest of 4
Hurdle (Req g minus delivered)-103.6 pp-1.1 ppleast demanding of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Genfit GNFT.PAFrance$571M+22%+28%-130%431.5×39.8%+143.5%
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%n/an/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%n/an/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%69.3×31.9%+27.2%
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%11.7×n/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%n/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%n/an/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%24.6×14.3%+15.4%
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%22.3×n/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%n/an/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%n/a-8.9%-1.3%
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%n/an/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%19.2×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Geron GERNUnited States$638M-21%+19%-8%17.4×n/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%n/an/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%21.5×n/an/a

Questions

Which companies are Genfit's closest peers?
The cockpit's peer set: Ascletis Pharma (1672.HK), 4D Molecular Therapeutics (FDMT), Boji Medical Technology (300404.SZ), Sana Biotechnology (SANA), Hvsen Biotechnology (300871.SZ), Alebund Pharmaceuticals (Jiangsu) (9637.HK), Wave Life Sciences (WVE), Climb Bio (CLYM).
Is Genfit expensive compared with its peers?
On forward p/e it trades at 431.5× against a peer median of 21.5×, most expensive of 8 in its peer set. For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +143%, so the hurdle is -104 pp: the price already allows for a slowdown.
How has Genfit stock performed?
Over six months to 18 Nov 2026 the shares returned +22.2% against -20.4% for the median peer; over one year +179.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.